Center Laboratories (4123) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.002x

Based on the latest financial reports, Center Laboratories (4123) has a cash flow conversion efficiency ratio of 0.002x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$46.61 Million ≈ $1.47 Million USD) by net assets (NT$19.64 Billion ≈ $618.69 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Center Laboratories - Cash Flow Conversion Efficiency Trend (2006–2024)

This chart illustrates how Center Laboratories's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Center Laboratories balance sheet liabilities for a breakdown of total debt and financial obligations.

Center Laboratories Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Center Laboratories ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Hangzhou Haoyue Personal Care Co Ltd
SHG:605009
0.031x
Guangdong Fuxin Technology Co. Ltd. A
SHG:688662
0.072x
Beijing Philisense Tech
SHE:300287
-0.021x
Koza Anadolu Metal Madencilik Isletmeleri AS
IS:KOZAA
0.122x
SolGold Plc
F:S8F
0.128x
Metalurgica Gerdau S.A
SA:GOAU3
0.053x
Sipef NV
BR:SIP
0.138x
Aeva Technologies, Inc. Common Stock
NYSE:AEVA
-0.447x

Annual Cash Flow Conversion Efficiency for Center Laboratories (2006–2024)

The table below shows the annual cash flow conversion efficiency of Center Laboratories from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see 4123 market cap overview.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 NT$18.05 Billion
≈ $568.82 Million
NT$415.71 Million
≈ $13.10 Million
0.023x +148.32%
2023-12-31 NT$20.22 Billion
≈ $636.92 Million
NT$-963.44 Million
≈ $-30.35 Million
-0.048x -383.21%
2022-12-31 NT$19.25 Billion
≈ $606.55 Million
NT$-189.88 Million
≈ $-5.98 Million
-0.010x +41.91%
2021-12-31 NT$21.09 Billion
≈ $664.61 Million
NT$-358.14 Million
≈ $-11.28 Million
-0.017x -29.96%
2020-12-31 NT$20.63 Billion
≈ $650.10 Million
NT$-269.56 Million
≈ $-8.49 Million
-0.013x +29.50%
2019-12-31 NT$15.46 Billion
≈ $487.02 Million
NT$-286.45 Million
≈ $-9.02 Million
-0.019x -146.39%
2018-12-31 NT$15.47 Billion
≈ $487.30 Million
NT$617.84 Million
≈ $19.47 Million
0.040x -66.54%
2017-12-31 NT$16.87 Billion
≈ $531.48 Million
NT$2.01 Billion
≈ $63.44 Million
0.119x +63.44%
2016-12-31 NT$15.82 Billion
≈ $498.51 Million
NT$1.16 Billion
≈ $36.41 Million
0.073x +886.07%
2015-12-31 NT$14.88 Billion
≈ $468.92 Million
NT$-138.29 Million
≈ $-4.36 Million
-0.009x -754.87%
2014-12-31 NT$6.94 Billion
≈ $218.54 Million
NT$-7.54 Million
≈ $-237.52K
-0.001x -113.13%
2013-12-31 NT$5.01 Billion
≈ $157.93 Million
NT$41.50 Million
≈ $1.31 Million
0.008x +77.01%
2012-12-31 NT$3.47 Billion
≈ $109.32 Million
NT$16.23 Million
≈ $511.33K
0.005x -85.23%
2011-12-31 NT$2.21 Billion
≈ $69.75 Million
NT$70.11 Million
≈ $2.21 Million
0.032x +1890.25%
2010-12-31 NT$2.18 Billion
≈ $68.76 Million
NT$-3.86 Million
≈ $-121.64K
-0.002x -109.56%
2009-12-31 NT$2.11 Billion
≈ $66.57 Million
NT$39.11 Million
≈ $1.23 Million
0.019x -76.35%
2008-12-31 NT$573.09 Million
≈ $18.06 Million
NT$44.86 Million
≈ $1.41 Million
0.078x -45.54%
2007-12-31 NT$471.17 Million
≈ $14.84 Million
NT$67.71 Million
≈ $2.13 Million
0.144x +1.12%
2006-12-31 NT$273.07 Million
≈ $8.60 Million
NT$38.81 Million
≈ $1.22 Million
0.142x --

About Center Laboratories

TWO:4123 Taiwan Drug Manufacturers - Specialty & Generic
Market Cap
$906.73 Million
NT$28.78 Billion TWD
Market Cap Rank
#9544 Global
#294 in Taiwan
Share Price
NT$39.00
Change (1 day)
-0.26%
52-Week Range
NT$33.60 - NT$49.35
All Time High
NT$236.72
About

Center Laboratories, Inc., a pharmaceutical company, develops, manufactures, and sells pharmaceuticals in Taiwan and internationally. The company offers general medication pharmaceuticals comprising antipyretics and analgesics, bronchodilators, anti-inflammatory preparations, antihistamines, expectorants, narcotic antitussives and expectorants, gastrointestinal preparations, non-narcotic antituss… Read more